Comparative Pharmacology
Head-to-head clinical analysis: BALZIVA 28 versus ENPRESSE 28.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BALZIVA 28 versus ENPRESSE 28.
BALZIVA-28 vs ENPRESSE-28
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
BALZIVA-28 is a combination estrogen-progestin oral contraceptive. Ethinyl estradiol provides estrogenic activity, while levonorgestrel acts as a progestin, primarily suppressing gonadotropin (FSH and LH) release from the pituitary, inhibiting ovulation, and causing changes in cervical mucus and endometrium to reduce sperm penetration and implantation.
ENPRESSE-28 is a combined hormonal contraceptive containing ethinyl estradiol and desogestrel. It acts by suppressing gonadotropin release (FSH and LH) from the pituitary, inhibiting ovulation, thickening cervical mucus to impede sperm penetration, and altering the endometrium.
One tablet (0.5 mg levonorgestrel and 0.1 mg ethinyl estradiol) orally once daily for 28 days, starting on the first day of menstrual cycle.
1 tablet (ethinyl estradiol 0.035 mg / norgestimate 0.25 mg) orally once daily for 21 days, followed by 7 placebo days.
None Documented
None Documented
2.5 hours; clinically relevant for dosing interval in renal impairment
Terminal elimination half-life is 18-24 hours, allowing once-daily dosing; steady-state achieved within 5-7 days.
Renal: 50-60% as unchanged drug; fecal: 30-40% as metabolites; biliary: <5%
Primarily renal excretion as unchanged drug (70-80%) and glucuronide conjugate (15-20%); biliary/fecal elimination accounts for <5%.
Category C
Category C
Oral Contraceptive
Oral Contraceptive